Patients with AMD may not need monthly injections

Researchers have found that, contrary to prvious clinical trial findings, monthly injections to counteract age-related macular degeneration (AMD) may not be necessary. The research is being presented at the 2014 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Orlando, Fla.

The investigators used a strategy called "treat and extend" to conduct the study, in which the frequency of office visits and injections were tailored to each patient's individual response to therapy. Following 185 patients over a three-and-a-half-year period, the average number of visits and injections was reduced from 12 to 8.3 times per year.

AMD is the leading cause of severe vision loss among people 50 years of age or older in . The findings could reduce the burden associated with frequent therapy, lowering the financial burdens on patients, families and government.

More information: Abstract Title: Long-Term Visual Outcomes for a Treat and Extend Anti-VEGF Regimen in Eyes with Neovascular Age-Related Macular Degeneration

add to favorites email to friend print save as pdf

Related Stories

New drug could help AMD sufferers

Jun 18, 2013

There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that ...

Cheaper AMD drug could lead to serious eye issues

Jun 18, 2012

A Queen's University study of two eye drugs used to treat wet Age-related Macular Degeneration (AMD) has determined the cheaper of the two could lead to eye inflammation, a potentially blinding adverse effect.

Recommended for you

Amblyopia Tx at young age results in good vision later

Jul 16, 2014

(HealthDay)—Most children treated for moderate amblyopia when younger than 7 years have good visual acuity at 15 years of age, according to a study published in the July issue of JAMA Ophthalmology.

User comments